In 2003, Matthias Peipp received his Ph.D. at the chair of genetics, Friedrich-Alexander-University, Erlangen-Nuremberg, Germany. In 2004, he moved to the Christian-Albrechts-University of Kiel (Kiel, Germany), where he studied effector mechanisms mediated by fully human EGFR-directed antibodies. Since 2006, Matthias is head of a research group at the Division of Stem Cell Transplantation and Immunotherapy (Kiel, Germany). In mid-2015 Matthias was awarded an endowed professorship for experimental antibody-based cancer immunotherapy from the German Cancer Aid. His current work is focused on the generation and functional characterization of engineered therapeutic antibodies and antibody derivatives to modulate immune effector cell recruitment.